ArticleScience advances2023

Inhibition of Parkinson's disease-related LRRK2 by type I and type II kinase inhibitors: Activity and structures.

Marta Sanz Murillo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.